EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes

Gwendolyne A Jack, Eleonora Avenatti, Sangeeta R Kashyap, Archana R Sadhu iD

The Journal of Clinical Endocrinology & Metabolism · 07.08.2025 · 110 (9) · e2852-e2863

DOI: 10.1210/clinem/dgaf301 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 27.05.2025. Verfasst von Gwendolyne A Jack und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine-New York Presbyterian, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Healthcare Disparities, Cardiovascular Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Weill Cornell Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite mounting evidence supporting the cardio-kidney benefits of sodium/glucose cotransporter 2 inhibitors (SGLT2i), significant disparities in their use exist among people with type 2 diabetes (T2D), cardiovascular, or kidney disease that reveals a significant disconnect between guidelines and practice. These discrepancies are particularly pronounced among women, minority races, and lower socioeconomic groups. These groups remain underrepresented in major cardiovascular trials, potentially leading to their exclusion from optimal therapies and increasing morbidity and mortality rates. This review aims to highlight disparities in the use of SGLT2i in populations with T2D, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease. It examines the factors that influence the prescription of SGLT2i within these populations and evaluates their downstream impact on clinical outcomes. Finally, the review summarizes recent clinical trial findings on strategies that enhance the adoption of SGLT2i and other cardioprotective agents through a multifaceted approach, aiming to improve real-world adoption for patients with T2D and/or cardiovascular and kidney diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Healthcare DisparitiesCardiovascular DiseasesHumans

Stichwörter der Autor:innen

SGLT2icardiovascular diseasechronic kidney diseasediabetes mellitusdisparities

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine-New York Presbyterian, New York, NY 10065, USA.
  • Division of Cardiology, Weill Cornell and Houston Methodist Academic Institute, Houston Methodist Hospital, Houston, TX 77030, USA.
  • Division of Endocrinology, Diabetes and Metabolism, Weill Cornell and Houston Methodist Academic Institute, Houston, TX 77030, USA.

ORCID-Profile: Archana R Sadhu

Förderung

  • Weill Cornell Medicine

Zitieren

APA

Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025). Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 110(9), e2852-e2863. https://doi.org/10.1210/clinem/dgaf301

Vancouver

Jack GA, Avenatti E, Kashyap SR, Sadhu AR. Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025;110(9):e2852-e2863. doi:10.1210/clinem/dgaf301

BibTeX
@article{Jack2025,
  author = {Jack, Gwendolyne A and Avenatti, Eleonora and Kashyap, Sangeeta R and Sadhu, Archana R},
  title = {Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {9},
  pages = {e2852--e2863},
  doi = {10.1210/clinem/dgaf301}
}
Kostenlos starten →